5

10

15

We claim:

- A method for synthesizing a nucleic acid molecule comprising at least one non-canonical nucleotide, comprising the steps of:
  - a) incubating a template nucleic acid in a reaction mixture under nucleic acid synthesis conditions containing (i) a mutant nucleic acid polymerase, wherein said polymerase has a reduced discrimination between canonical and non-canonical nucleoside triphosphates, and (ii) at least one non-canonical nucleoside triphosphate, wherein said non-canonical nucleoside triphosphate is incorporated into the synthesized nucleic acid in place of only one canonical nucleoside triphosphate, and
  - b) obtaining the synthesis of a nucleic acid molecule comprising at least one non-canonical nucleotide.
- 2. The method of claim 1 wherein the template nucleic acid is DNA.
- The method of claim 1 wherein the template nucleic acid is RNA.
- 4. The method of claim 1 wherein a nucleic acid molecule comprising at least one non-canonical nucleotide is synthesized by extension of a primer molecule, at least part of which is sufficiently complementary to a portion of the template to hybridize therewith.

QB3\222428.1

- 5. The method of claim 1 wherein a nucleic acid molecule comprising at least one non-canonical nucleotide is synthesized de novo without using a primer molecule.
- $\label{eq:continuous} \textbf{6.} \quad \text{ The method of claim 1 wherein the polymerase is an } \\ \textbf{RNA polymerase.}$
- 7. The method of claim 1 wherein the polymerase is a ~7-type RNA polymerase.
- The method of claim 1 wherein the polymerase is selected from the group consisting of T7 and SP6 RNA polymerases.
- 9. The method of claim 1 wherein the mutant polymerase is an RNA polymerase and the non-canonical nucleoside triphosphate is a 2'-fluoro-nucleoside triphosphate.
- 10. The method of claim 1 wherein the synthesized nucleic acid molecule has an altered susceptibility to a ribonuclease or a deoxyribonuclease compared to a nucleic acid which is synthesized using the corresponding non-mutant nucleic acid polymerase.

- 11. The method of claim 1 wherein the synthesized nucleic acid molecule is selected from the group consisting of a ribozyme or a nucleic acid molecule used for gene therapy, in a vaccine, in an antiviral composition, in an antimicrobial composition, in an antisense composition for regulating gene expression, in a composition for hybridization to a complementary nucleic acid, or as a probe for detection of a complementary nucleic acid.
  - 12. The method of claim 1 wherein the synthesized nucleic acid molecule is single-stranded.
  - 13. A kit for performing the method of claim 1, comprising a mutant nucleic acid polymerase which has reduced discrimination between canonical and non-canonical nucleoside triphosphates and data or information describing conditions under which the method of claim 1 may be performed.
  - 14. The kit of claim 13, wherein the nucleic acid polymerase is a mutant T7-type RNA polymerase.
    - 15. The kit of claim 13, wherein the nucleic acid polymerase is a T7 RNA polymerase comprising an altered amino acid at position 639.
    - 16. The kit of claim 13, wherein the nucleic acid polymerase is SP6 RNA polymerase comprising an altered amino acid at position 631.